According to our new research study on "Eye Allergy Treatment Market Forecast to 2031 - Global Analysis - by Treatment, Indications, Distribution Channel, and Geography," the market is expected to grow from US$ 3,924.88 million in 2024 to US$ 5,972.22 million by 2031; it is estimated to record a CAGR of 6.3% from 2025-2031. Key factors driving the growth of the eye allergy treatment market are the increasing eye allergy prevalence, surging geriatric population, and prescription to over-the-counter transition.

The scope of the eye allergy treatment market report includes the assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. Asia Pacific is anticipated to register the fastest CAGR in the eye allergy treatment market from 2025 to 2031. The rapid urbanization in major countries such as China, India, and Southeast Asia has caused a rise in the pollution level, which in turn has made ocular allergies like allergic conjunctivitis more common. The eye health awareness is rising due to better access to health care and government initiatives; thus, patients are more encouraged to go for medical treatment instead of home remedies.

The massive and still growing population of the region, which contains a large youth segment that is prone to being irritated by outdoor allergens and screens, increases the patient pool even more, supporting the eye allergy treatment market growth in the Asia Pacific.

Besides, the rise in disposable incomes allows consumers to buy advanced treatments such as antihistamine eye drops, mast-cell stabilizers, and combination therapies. The pharmaceutical companies are also making huge investments in the region because of the favorable regulatory reforms and growing distribution networks, which are helping them to make innovative products more available. The rise of online pharmacies and telehealth services has made the treatment more accessible in rural and underserved areas, accelerating the growth of the Asia-Pacific eye allergy treatment market in the near future.

In the People's Republic of China, allergic conjunctivitis (AC) is a very common health issue among the people. A 2024 multicenter study estimates that about 20-40% of the urban population suffers from eye allergies that are caused by environmental factors-creating a problem that affects millions of people every year. In the southern part of the country, the prevalence among children is more than 18%, and there are 1,043 confirmed cases of eczema with conjunctival irritation often occurring together.

The rise in cases of AC is mainly attributed to the rapid Industrial growth and the accompanying air pollution. Besides that, people moving to cities also means more exposure to indoor allergens and cars' emissions, which, in turn, are the reasons for the increase in the number of cases in such huge cities as Beijing and Shanghai during the last five years, thus becoming a significant factor supporting the eye allergy treatment market in the region.

In addition, the eye allergy treatment market has been facilitated by innovations, coupled with ongoing research into pollution mitigation. Additionally, a cross-sectional study published in May 2025 in Japan found that AC affected 20-30% of adults and even up to 49.3% of adolescents, with over 90% of cases being seasonal AC, which is marked by itching, redness, and watering of the eyes during the pollen seasons. Perennial forms are seen in 16.9% of the patients, which are mostly associated with the pollen of cedar and cypress trees, thus affecting more than 25 million people in the country.

A June 2025 prospective study reported that eye cream with topical epinastine is a better option for perennial AC than traditional drops, as it improves compliance by 30% with applying it twice a day instead of drops. The Kayumidas app was tested in 2024 trials and found to be very effective in helping patients with eye-drop adherence and controlling the symptoms of AC and rhinitis, further fueling the growth of the eye allergy treatment market.

Moreover, dupilumab's increasing real-world use in July 2025 for severe atopic cases resulted in 50-60% symptom reduction, which indicates a trend change towards biologics for refractory ocular allergies. These developments, along with the integration of pollen forecasting, are tackling Japan's cedar pollen epidemic, which helps a lot in managing the disease even when the environmental challenges are still there, bolstering the eye allergy treatment market growth. Therefore, the factors mentioned above are promoting a favorable environment for the eye allergy treatment market in the region.

Alcon AG, Bausch + Lomb Corporation, AdvaCare Pharma USA LLC, AbbVie Inc., Sun Pharmaceutical Industries Ltd, Grevis Pharmaceuticals Pvt Ltd., Santen Pharmaceutical Co. Ltd., Bayer AG, ZEXUS PHARMA, and Lupin Ltd. are among the leading companies profiled in the eye allergy treatment market report.

Based on treatment, the eye allergy treatment market is divided into oral medication, allergy shots, and eye drops. By indications, the market is segmented into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, and giant papillary conjunctivitis. In terms of distribution channel, the eye allergy treatment market is classified into hospital pharmacies, online pharmacy, and drug stores. Geographically, the eye allergy treatment market is categorized into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East and Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).

Contact Us
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com